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Background: Histone deacetylase inhibitor romidepsin has demonstrated durable clinical responses and tolerability
in patients with relapsed/refractory peripheral and cutaneous T-cell lymphoma (PTCL, CTCL). Selection of novel drug
therapies for patients with relapsed/refractory aggressive lymphoma requires not only considerations regarding
efficacy but also careful evaluation of toxicities as well as overall clinical benefit. The purpose of this analysis was to
examine common adverse events (AEs) reported in pivotal trials of romidepsin in relapsed/refractory PTCL or CTCL
and to more clearly define the overall AE profile in these populations.
Methods: Patients with relapsed/refractory PTCL or CTCL were treated with romidepsin at 14 mg/m2 as a 4-hour
intravenous infusion on days 1, 8, and 15 of 28-day cycles for up to 6 cycles; patients with at least stable disease
could extend therapy until progressive disease or another withdrawal criterion was met. All enrolled patients who
received ≥ 1 dose of romidepsin were included in the AE analyses.
Results: Overall, safety profiles of common AEs were similar, although patients with relapsed/refractory PTCL had
more frequent hematologic toxicities and grade ≥ 3 infections. In both patient populations, the greatest incidence
of grade ≥ 3 AEs and the majority of discontinuations due to AEs occurred during cycles 1–2. Early discontinuations
were primarily related to infection, thrombocytopenia, or electrocardiogram abnormalities, confirming the need to
closely monitor patients with poor bone marrow reserve or other comorbidities. Despite this, 28% of patients with
relapsed/refractory PTCL and 36% of patients with relapsed/refractory CTCL continued on romidepsin treatment
for ≥ 6 cycles.
Conclusions: This study demonstrates that patients with relapsed/refractory PTCL or CTCL have similar AE profiles
with romidepsin treatment, although patients with PTCL experienced more frequent and more severe hematologic
toxicities and more frequent grade ≥ 3 infections. The greatest incidence of grade ≥ 3 AEs and the majority of
discontinuations due to AEs occurred during treatment cycles 1–2. Extended dosing of romidepsin can be tolerated
in responding patients.
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Romidepsin—a structurally unique, potent, bicyclic class
1 selective histone deacetylase inhibitor [1-3]—is approved
by the United States Food and Drug Administration for
patients with cutaneous T-cell lymphoma (CTCL) who
have received at least one prior systemic therapy and pa-
tients with peripheral T-cell lymphoma (PTCL) who have
received at least one prior therapy [4].
CTCL is a primarily indolent, heterogeneous group of
non-Hodgkin lymphoma (NHL) with a poor prognosis
in advanced stage disease [5]. CTCL arises when CD4+
malignant T cells localize to the skin [6]; however, in
later disease stages, patients may also have lymph node,
blood, and/or visceral involvement [7]. Patients with CTCL
often experience intolerable itching (pruritus), visual
(cosmetic) skin changes, and frequent infections [8-10].
PTCL is an aggressive, uncommon form of NHL typically
associated with a poor prognosis [11]. Disease arises from
mature, post-thymic T cells or natural killer (NK) cells
[12]. Clinical features vary widely in this heterogeneous
group of diseases, with varying symptoms and organ
involvement. However, hematologic abnormalities are
common in patients with PTCL and may be due to
disease involvement in the bone marrow or prior my-
elosuppressive chemotherapy [13]. Durable clinical re-
sponses in PTCL or advanced-stage CTCL are difficult to
achieve [5,12,14].
A phase 1 trial conducted by the National Cancer
Institute (NCI) demonstrated activity of romidepsin in
T-cell lymphoma [15]. A phase 2 NCI trial was then
initiated to evaluate the safety and efficacy of romidepsin
in relapsed or refractory (R/R) CTCL or PTCL [16,17].
Based on initial results from the NCI trial, separate pivotal
registration trials were also conducted in each indication:
GPI-04-0001 in R/R CTCL [18] and GPI-06-0002 in R/R
PTCL [13].
In GPI-04-0001, single-agent romidepsin therapy re-
sulted in durable responses in patients with R/R CTCL
who had received at least one prior systemic therapy with
an objective response rate (ORR) of 34% (33/96, including
6% [6/96] complete response [CR]) and median duration
of response (DOR) of 15 months (range, < 1-20+; median
follow-up not reported) [18]. Similar responses to romi-
depsin were observed in all stages of disease and across
all disease compartments: skin, lymph nodes, and blood
[18]. The most common romidepsin-related adverse events
(AEs) in CTCL were gastrointestinal or asthenic condi-
tions, primarily grade 1–2 [18].
In GPI-06-0002, patients with R/R PTCL achieved dur-
able responses with romidepsin treatment, with an ORR
of 25% (33/130, including 15% [19/130] confirmed/uncon-
firmed CR) [13] and median DOR of 28 months (range <
1-48+) with median follow-up of 22.3 months [19]. Romi-
depsin demonstrated comparable efficacy in the 3 mostcommon PTCL subtypes: PTCL not otherwise specified,
angioimmunoblastic T-cell lymphoma, and anaplastic
lymphoma kinase–negative anaplastic large cell lymph-
oma. Patient baseline characteristics or prior treat-
ments did not affect the response [13]. The most frequent
romidepsin-related AEs were nausea and asthenia/fatigue,
which were primarily grade 1–2 and did not result in drug
discontinuation [13].
In both R/R CTCL and R/R PTCL, romidepsin was not
correlated with clinically meaningful QTc prolongation
[13,18,20], and a similar toxicity profile was observed
[4,13,18]. The purpose of this analysis was to examine
common AE data in detail from the pivotal trials of romi-
depsin in R/R CTCL and R/R PTCL and to evaluate the
AE profile in these 2 groups of patients.Results
Patient characteristics
Baseline characteristics in R/R CTCL or R/R PTCL were
similar and were previously described [13,18]. Notably, pa-
tients with R/R CTCL or R/R PTCL in these trials tended
to be heavily pretreated (median of 2 [PTCL] or 3 [CTCL]
prior systemic therapies [range, 1–8 in both]), and > 70%
of patients in each trial had advanced disease (III-IV for
PTCL, IIB-IVA for CTCL). The majority of patients re-
ceived prior chemotherapy, with fewer patients receiving
prior monoclonal antibodies, immunotherapy, or novel
agents. All patients with R/R CTCL had previously re-
ceived at least one topical therapy [13,18].Romidepsin exposure
The median durations of treatment were 1.4 months (range, <
0.1-35.7 months) and 3.5 months (<0.1-26.7 months) for
patients with PTCL or CTCL, respectively. There was a
significant population of early withdrawals during cycles
1–2: 72 (55%) and 28 (27%) patients with PTCL or CTCL,
respectively. For patients with PTCL, these early with-
drawals were due to disease progression (n = 50), adverse
events (n = 16), withdrawal of informed consent (n = 2), or
other reasons (n = 4). For patients with CTCL, these early
withdrawals were due to disease progression (n = 10), ad-
verse events (n = 11), withdrawal of informed consent
(n = 6), or other reasons (n = 1). Although the AEs lead-
ing to early discontinuation varied widely in both patient
populations, they were primarily related to infections,
thrombocytopenia, or ECG abnormalities. Early discon-
tinuation due to hematologic AEs was uncommon in both
patient populations. Many patients tolerated romidepsin
for at least 6 cycles: 36 (28%) and 36 (36%) patients with
PTCL or CTCL, respectively. Patients received routine an-
tiemetic prophylaxis prior to each romidepsin dose. The
most common antiemetics administered were 5HT3 an-
tagonists ondansetron and granisetron.
Foss et al. Biomarker Research 2014, 2:16 Page 3 of 10
http://www.biomarkerres.org/content/2/1/16Incidence of common AEs in PTCL or CTCL populations
A similar safety profile of common AEs was seen in the
PTCL and CTCL populations, and nausea/vomiting was
the most frequent AE and drug-related AE (all grade) in
both populations (Figure 1). Overall, a numerically higher
incidence of grade ≥ 3 AEs (66% and 52% vs 32% and 24%
for total or drug-related grade ≥ 3 AEs for patients with
R/R PTCL or CTCL, respectively) and a higher incidence
of hematologic toxicities (24%, 21%, and 11% grade ≥ 3
thrombocytopenia, neutropenia, and anemia, respectively,
for patients with R/R PTCL and 0%, 4%, and 3%, respect-
ively, for patients with R/R CTCL) were reported for pa-
tients with R/R PTCL. The incidences of grade ≥ 3
infections (all types pooled) were 19% and 8% for patients
with R/R PTCL or CTCL, respectively, although the ma-
jority of infections were not related to romidepsin treat-
ment per the investigator (6% and 5% drug-related
grade ≥ 3 infections for patients with R/R PTCL or CTCL,
respectively; Figure 1, Table 1). In both the R/R PTCL andFigure 1 Total adverse events (AEs) and drug-related AEs in patients
(PTCL, CTCL).CTCL populations, the incidence of all grade and grade ≥
3 AEs (overall and drug-related) was highest during the
first few cycles of treatment (Figure 2) and declined
thereafter.
Impact of patient characteristics on toxicity profile in
patients with R/R PTCL
Common AEs were examined by subgroups of patients
with R/R PTCL to determine whether baseline or disease
characteristics can predict tolerability to romidepsin. The
factors considered were PTCL subtype, age, International
Prognostic Index score, type and number of prior therap-
ies, and presence of bone marrow involvement. The inci-
dence of treatment-related grade ≥ 3 infection (20% vs 4%)
and neutropenia (50% vs 14%) was higher in patients
with R/R PTCL who received prior monoclonal anti-
body (MAb) therapy (primarily alemtuzumab [n = 7] or ri-
tuximab [n = 11]); likewise there was a higher incidence
of treatment-related grade ≥ 3 thrombocytopenia (38%with relapsed/refractory peripheral or cutaneous T-cell lymphoma
Table 1 Listings of infections with overall incidence in > 5%
of patients with PTCL or CTCL
Total AEs Drug-related AEs
Subgroup All grade grade ≥ 3 All grade Grade≥ 3
Cellulitis, n (%)
PTCL 6 (5) 5 (4) 3 (2) 3 (2)
CTCL 2 (2) 0 0 0
Pneumonia, n (%)
PTCL 8 (6) 6 (5) 2 (2) 2 (2)
CTCL 1 (0) 0 0 0
Sepsis, n (%)
PTCL 7 (5) 7 (5) 2 (2) 2 (2)
CTCL 4 (4) 4 (4) 2 (2) 2 (2)
Nasopharyngitis, n (%)
PTCL 6 (5) 0 0 0
CTCL 4 (4) 0 0 0
Upper respiratory tract infection, n (%)
PTCL 11 (8) 2 (2) 7 (5) 2 (2)
CTCL 6 (6) 0 1 (1) 0
Urinary tract infection, n (%)
PTCL 9 (7) 1 (1) 2 (2) 1 (1)
CTCL 3 (3) 0 1 (1) 0
Skin infection, n (%)
PTCL 2 (2) 0 1 (1) 0
CTCL 7 (7) 1 (1) 2 (2) 0
AE, adverse event; CTCL, cutaneous T-cell lymphoma; PTCL, peripheral
T-cell lymphoma.
Figure 2 Incidence of any grade and grade ≥ 3 adverse events
(AEs) by cycle for patients with relapsed/refractory peripheral
or cutaneous T-cell lymphoma (PTCL, CTCL). Numbered bars
represent number of patients treated in each cycle.
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tients. While patients who had received prior MAbs
had lower baseline blood counts compared to other
patients in the studies, there was no relationship be-
tween baseline lab values and incidence of grade ≥ 3
cytopenias. For the majority of patients with PTCL or
CTCL, platelet count recovered between each treat-
ment cycle, consistent with the reported mechanism
for romidepsin-induced thrombocytopenia (Figure 3)
[21]. The incidence of treatment-related grade ≥ 3 AEs
was not high enough to perform an equivalent ana-
lysis for patients with R/R CTCL, and only 4 CTCL
patients had prior MAb exposure.
Serious AEs, hospitalizations, dose adjustments, and
discontinuations
Infections were the most common serious AEs and reason
for hospitalization in patients with R/R PTCL or CTCL
(Table 3). Dose interruptions due to AEs occurred in 47%
of patients with R/R PTCL and 34% of patients with R/R
CTCL. Dose reductions due to AEs occurred in 11% of pa-
tients with R/R PTCL and 14% of patients with R/R CTCL
(Table 4). For patients with PTCL, dose interruptions weremost commonly due to thrombocytopenia (18%), infec-
tions (all types pooled; 12%), and neutropenia (11%);
thrombocytopenia was the only AE that led to dose reduc-
tion in > 2 patients (n = 4). For patients with CTCL, dose
interruptions were most commonly due to infections (all
types pooled; 13%), neutropenia (3%), fatigue (3%), and
hypomagnesemia (3%); vomiting was the only AE that led
to dose reduction in > 2 patients (n = 3). Rates of discon-
tinuation due to AEs were low in both patient popula-
tions (Table 3). The majority of discontinuations due
to AEs for patients with R/R PTCL occurred during
cycles 1–2 (Figure 4). For patients with R/R CTCL,
42% (10/24) of discontinuations occurred during cycle
1 (Figure 4).
The most common AEs leading to discontinuation for
patients with R/R PTCL were thrombocytopenia in 3 pa-
tients and infection in 6 patients (3 pneumonia, 2 sepsis,
1 upper respiratory infection) and for patients with R/R
CTCL were asthenic conditions in 4 patients and infec-
tion in 5 patients (1 Epstein-Barr viral infection, 4 upper
respiratory tract infections) (Table 3).
Table 2 Incidence of treatment-related grade ≥ 3 adverse events by patient characteristics in patients with PTCLa
No. Infection Thrombocytopenia Neutropenia Anemia Asthenic conditions Nausea and vomiting
PTCL subtypes
PTCL NOS 69 4 20 17 4 7 4
AITL 27 4 30 22 7 4 0
ALK-1–negative ALCL 21 5 24 14 0 5 5
Other 14 21 31 36 14 0 7
Age
< 65 years 86 6 23 22 6 4 6
≥ 65 years 45 7 22 16 4 9 0
International Prognostic Index score
0-1 31 3 19 13 10 0 7
≥ 2 100 7 24 22 4 7 3
Prior systemic therapies
< 3 83 6 15b 21 8 5 5
≥ 3 48 6 38b 19 0 6 2
Prior stem cell transplant
Yes 21 0 33 10 5 5 0
No 110 7 21 22 6 6 5
Prior monoclonal antibody therapyc
Yes 20 20d 35 50e 5 5 0
No 111 4d 21 14e 5 5 5
Bone marrow involvement
Yes 37 8 30 24 5 5 0
No 94 5 20 18 5 5 5
AITL, angioimmunoblastic T-cell lymphoma; ALCL, anaplastic large cell lymphoma; ALK, anaplastic lymphoma kinase; PTCL NOS, peripheral T-cell lymphoma not
otherwise specified.
aAll comparisons except those noted below were not significant (P > .05).
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Single-agent romidepsin has demonstrated clinical activ-
ity in patients with R/R CTCL (34% ORR including 6%
CR and median DOR of 15 months) [18] and PTCL
(25% ORR including 15% confirmed/unconfirmed CR
and median DOR of 28 months) [19]. The types of com-
mon AEs reported with romidepsin therapy were similar
across the 2 indications, including hematologic toxicities,
gastrointestinal events, asthenia/fatigue, or infections
[13,16-18]. Approved romidepsin dosing was generally
well tolerated in patients with R/R CTCL or PTCL, with
AEs resulting in < 20% of patients discontinuing therapy
and < 15% of patients requiring dose reductions.
Despite the similar AE profiles, there were some notable
differences across the indications. Patients with R/R PTCL
experienced more frequent and more severe hematologic
toxicities and more frequent grade ≥ 3 infections (all types
pooled). Although it is recognized that the cause of the
thrombocytopenia with romidepsin is not due to a directmyelosuppressive effect but rather to defective megakar-
yocytic budding [21], it seems likely that the hematologic
AEs observed in patients with PTCL may be attributed
to a reduced megakaryocyte pool due to prior myelo-
suppressive chemotherapy and/or bone marrow disease
involvement [13]. In this study, patients with R/R PTCL
who had received ≥ 3 prior systemic therapies had signifi-
cantly higher treatment-related grade ≥ 3 thrombocytopenia
compared with those who had < 3 prior systemic therap-
ies. Prior monoclonal antibody exposure in patients with
R/R PTCL (predominantly alemtuzumab or rituximab)
was associated with a significantly higher incidence of
treatment-related grade ≥ 3 infection and neutropenia.
This analysis could not be performed for patients with
R/R CTCL, as rates of treatment-related grade ≥ 3 infec-
tions were too low to assess differences, and only 4 pa-
tients had prior MAb exposure.
For this analysis, all infection types were pooled to accur-
ately reflect the total infection risk. Because AE reporting
Figure 3 Thrombocytopenia recovery by cycle of romidepsin treatment for patients with relapsed/refractory peripheral T-cell lymphoma
(A) or cutaneous (B) T-cell lymphoma. BL, baseline; C, cycle, D, day.
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may fall below the cutoff of those reported as “common”
AEs, and infection risk may be overlooked. Additionally,
comparing infection risk across agents is difficult when
they are not pooled. In the pivotal study of pralatrexate for
the treatment of R/R PTCL, only the specific infections
seen in ≥ 10% of patients (upper respiratory tract infection
and sinusitis) were reported [22]. In patients with R/R
CTCL treated with vorinostat, only upper respiratory in-
fection was reported in ≥ 10% of patients [23]. No specific
infection type was reported in ≥ 10% of patients with R/R
PTCL or CTCL treated with romidepsin. However, when
pooled, 55% of patients with R/R PTCL and 50% of
patients with R/R CTCL (19% and 8% grade ≥ 3,
respectively) experienced infection during romidepsin
treatment. Notably, most of the infections were not con-
sidered related to romidepsin treatment and thus may
have been due to the increased risk of infection related to
disease state or prior therapies. As a result of com-
promised skin integrity, patients with CTCL experience
frequent infections [9,10,24,25].Because of the risk of infection in patients with T-cell
lymphoma, steps to minimize infectious complications
should be taken. Romidepsin does not require a central IV
catheter, which has been associated with an increased risk
of infection in patients with CTCL [26]. Strict adherences
to aseptic technique should be taken when establishing a
peripheral IV line for drug administration. Additionally, for
patients with poor immune function due to heavy pre-
treatment or prior monoclonal antibody therapy, prophy-
lactic antibiotic or antiviral medication may be appropriate.
Electrocardiogram changes were described in studies with
romidepsin [27-29]; however, there was no evidence of
myocardial damage or significant changes in left ventricular
ejection fraction in romidepsin clinical trials with routine
cardiac monitoring [28,29]. It was shown that clinically in-
significant QTc effects observed with romidepsin treatment
were likely related to antiemetic administration [20,28,30].
Changes in ECG parameters, including QTc intervals, are a
class effect of 5-hydroxytryptamine 3 receptor agonist anti-
emetics [31,32]. Granisetron may have less of an effect on
the QT interval than other 5-hydroxytryptamine 3 receptor





Dose reduction due to adverse events, n (%) 14 (11) 14 (14)
Dose interruptions due to adverse events, n (%) 61 (47) 35 (34)
Discontinuation, n (%)
Progressive disease 78 (60) 22 (22)
Adverse event 22 (17) 24 (24)
Adverse event related to romidepsin treatment 11 (8) 17 (17)
Othera 7 (5) 26 (26)
CTCL, cutaneous T-cell lymphoma; PTCL, peripheral T-cell lymphoma.
aMost often refers to withdrawal of consent.
Table 3 Total and drug-related serious adverse events,
hospitalizations, and discontinuations
Total AEs Drug-related AEs
Subgroup SAEs Hosp D/C SAEs Hosp D/C
Anemia, n (%)
PTCL 2 (2) 2 (2) 0 2 (2) 2 (2) 0
CTCL 1 (1) 1 (1) 0 1 (1) 1 (1) 0
Neutropenia, n (%)
PTCL 7 (5) 7 (5) 2 (2) 5 (4) 5 (4) 2 (2)
CTCL 2 (2) 0 1 (1) 2 (2) 0 1 (1)
Thrombocytopenia, n (%)
PTCL 2 (2) 1 (1) 3 (2) 1 (1) 1 (1) 3 (2)
CTCL 0 0 1 (1) 0 0 1 (1)
Nausea and vomiting, n (%)
PTCL 6 (5) 6 (5) 0 4 (3) 4 (3) 0
CTCL 0 0 0 0 0 0
Asthenic conditions, n (%)
PTCL 2 (2) 2 (2) 2 (2) 0 0 1 (1)
CTCL 2 (2) 1 (1) 4 (4) 1 (1) 1 (1) 4 (4)
Infections, n (%)
PTCL 25 (19) 21 (16) 6 (5) 6 (5) 3 (2) 2 (2)
CTCL 8 (8) 8 (8) 5 (5) 5 (5) 5 (5) 3 (3)
AE, adverse event; CTCL, cutaneous T-cell lymphoma; D/C, discontinuations;
Hosp, hospitalizations; PTCL, peripheral T-cell lymphoma; SAEs, serious
adverse events.
Figure 4 Patient discontinuation due to adverse events by cycle of ro
peripheral or cutaneous T-cell lymphoma (PTCL, CTCL).
Foss et al. Biomarker Research 2014, 2:16 Page 7 of 10
http://www.biomarkerres.org/content/2/1/16agonist antiemetics [32]. Despite the use of prophylactic
antiemetics, > 50% of patients with R/R PTCL or CTCL
treated with romidepsin experience drug-related nausea
and/or vomiting, although the majority of events are grade
1–2 [4,29].
The greatest incidence of all grade and grade ≥ 3 AEs
and the majority of discontinuations due to AEs occurred
during cycles 1–2. Early discontinuations primarily related
to infection, thrombocytopenia, or ECG abnormalities
confirm the need to closely monitor heavily pretreated
patients, in particular those who have received prior
monoclonal antibody therapy or those with comorbidities,
with consideration of prophylactic antibiotic or antiviral
medication, or a lower initial romidepsin dose of 10 or
12 mg/m2 in such patients. Despite this, however, 28%
and 36% of patients with R/R PTCL or CTCL, respect-
ively, tolerated romidepsin for at least 6 cycles.midepsin treatment in patients with relapsed/refractory
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Single-agent romidepsin leads to durable response in a
subset of patients with R/R PTCL or CTCL. This study
demonstrated that patients with R/R PTCL or CTCL have
similar AE profiles with romidepsin treatment, although
patients with PTCL experienced more frequent and more
severe hematologic toxicities and more frequent grade ≥ 3
infections. Extended dosing of romidepsin is feasible in
responding patients without cumulative toxicities.Methods
Study design and eligibility criteria
Study design and eligibility criteria for these 2 similarly
designed phase 2, non-randomized, international, multi-
center, single-arm studies in R/R CTCL (GPI-04-0001)
or R/R PTCL (GPI-06-0002) were previously described
[13,18]. GPI-04-0001 was a study of romidepsin for the
treatment of patients with stage IB to IVA CTCL who had
received at least one prior systemic therapy [18]. GPI-06-
0002 was a study of romidepsin for the treatment of
patients with histopathologically confirmed PTCL who
had received at least one prior systemic therapy.
Patients on both trials had adequate organ function and
no known significant cardiac abnormalities (eg, congenital
long QT syndrome, QTc interval > 480 msec, recent myo-
cardial infarction, coronary artery disease, congestive heart
failure, cardiac arrhythmia requiring anti-arrhythmic me-
dications, ventricular tachycardia, ventricular fibrillation,
torsades de pointes, or cardiac arrest). Concomitant use of
drugs known to significantly prolong the QTc interval and
CYP3A4 inhibitors was disallowed. Because hypokalemia
and hypomagnesemia can be associated with electro-
cardiogram (ECG) abnormalities [28], patients must have
had normal levels of serum potassium and serum magne-
sium; low levels could be corrected with supplementation
to meet inclusion criteria. Both studies were conducted in
accordance with the Guidelines of the World Medical As-
sociation Declaration of Helsinki in its revised edition
(Washington, 2002), the guidelines for current Good Clin-
ical Practice (CPMP/ICH/135/95), the requirements of
Directive 2001/20/EC (European Investigators only), all
applicable US FDA regulations (US Investigators only) as
well as the demands of national drug and data protection
laws and other applicable regulatory requirements, as ap-
propriate. For both trials, the protocol, informed consent
form, and other relevant study documentation were
approved by the appropriate institutional review board or
independent ethics committee at each study site (for
primary author: Yale University School of Medicine
Human Investigation Committee, Suite 204, 47 College St,
New Haven, CT 06520). All patients provided written
informed consent before any study-specific procedure was
performed.Patients on both trials received romidepsin 14 mg/m2
as a 4-hour intravenous infusion on days 1, 8, and 15 of
each 28-day cycle for up to 6 cycles; patients with at least
stable disease could extend therapy until progressive dis-
ease or another withdrawal criterion was met. This dose
and schedule were based on results from the NCI phase
2 trials of patients with R/R CTCL [16] or PTCL [17],
and is the Food and Drug Administration–approved
dosing in both indications [4].Safety assessments
Adverse event (AE) recording was similar in both the
CTCL and PTCL studies, with toxicities classified ac-
cording to the Medical Dictionary for Regulatory Activities
Version 12.0, and AE severity was graded according to NCI
Common Terminology Criteria for Adverse Events Version
3.0. AEs were recorded on days 1, 8, and 15 of every cycle
for all patients; patients with R/R PTCL also had AEs re-
corded on day 22 of every cycle. Drug-related AEs were de-
fined as those considered by the investigator to have a
possible, probable, or very likely/certain relationship to the
study drug. Dose adjustment criteria were similar across
the 2 studies. Briefly, grade 3–4 nonhematologic toxicities
and grade 3–4 neutropenia or thrombocytopenia resulted in
dose interruption. One permanent dose reduction to
10 mg/m2 romidepsin as a 4-hour IV infusion on days 1, 8,
and 15 of each 28-day cycle was permitted. Following dose
reduction, if the AE recurred, the patient was discontinued
from the study. Common AEs reported during these studies,
specifically anemia, neutropenia, thrombocytopenia, nausea/
vomiting, asthenic conditions, and infections (all types
pooled), are the focus of the analyses described in this
manuscript.
Statistical methods
In both studies, all enrolled patients who received at least
one dose of romidepsin were included in the safety
analysis. In the analysis of treatment-related grade ≥ 3
AEs by patient characteristics, the percentages of patients
with common AEs in various patient subgroups were
compared by Fisher’s exact test, with P < .05 demonstrat-
ing significant differences in AE rates.Competing interests
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